Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Company Transformation - 2026 is anticipated to be a transformative year for Ionis, building on the momentum from 2025, which was also a significant year for the company [5][6] - Ionis transitioned from a research-focused entity to a fully integrated commercial biotechnology company, achieving two independent product launches: TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) prophylaxis [5][6] Product Launches and Pipeline - **TRYNGOLZA**: - First FDA-approved medicine for FCS, launched successfully in 2025 [5] - Expected to expand into severe hypertriglyceridemia (sHTG) with a PDUFA date of June 30, 2026, representing a multibillion-dollar market opportunity [6][12] - **DAWNZERA**: - Launched in September 2025, with $8 million in revenue reported for the year [21] - Primarily attracting switch patients from existing therapies, particularly TAKHZYRO [25] Clinical Trials and Data Readouts - Anticipation of five phase 3 readouts from partnered pipelines in 2026, including successful results for bepirovirsen for chronic HBV [7] - New phase 3 trials planned for salanersen (spinal muscular atrophy) and sapablursen (polycythemia) [8] Financial Guidance and Revenue Expectations - Initial revenue guidance for TRYNGOLZA was $820-$825 million, which is expected to be revised upwards due to priority review status for sHTG [9][10] - Ionis aims to reduce net operating loss and provide detailed product-level revenue guidance in the upcoming Q1 earnings call [10] Pricing Strategy - Pricing for TRYNGOLZA is expected to be in the range of $10,000-$20,000 net price, with considerations for competitive pricing against a new entrant in the FCS space [17] - The company is focused on maximizing patient access while preserving value for stakeholders [13][17] Clinical Data and Safety Observations - Positive phase 3 data for triglyceride lowering in sHTG, showing over 70% reduction in triglycerides and 85% reduction in acute pancreatitis attacks [12][19] - Observations of a small increase in hepatic fat during treatment, which is not considered a toxicity and is expected to normalize over time [20] Future Studies and Market Potential - The CARDIO-TTRansform study is set to provide significant data on ATTR cardiomyopathy, with peak market sales for WAINUA expected to exceed $5 billion [36] - The study aims to demonstrate the benefits of combining silencer and stabilizer therapies, which could enhance treatment outcomes for patients [37][38] Angelman Syndrome Study - The phase 3 study for ION582 will focus on an 80-milligram dose, as long-term data indicated greater efficacy without safety concerns [46][47] - Enrollment is progressing well, with expectations to complete this year and report data next year [47][48] Additional Insights - The company is strategically managing the launch of DAWNZERA with a free drug program to facilitate patient access while navigating payer negotiations [23][24] - Ionis is committed to providing comprehensive data sets from ongoing studies, which will support its market positioning and product efficacy claims [40][41]

Core Viewpoint - Recently, Huaron (Tianjin) Biotechnology Co., Ltd. was established with a registered capital of 10 million RMB, fully owned by Luoyang Huaron Biotechnology Co., Ltd. [1] Company Overview - The legal representative of Huaron (Tianjin) Biotechnology Co., Ltd. is Wei Qunming [1] - The company is classified under the scientific research and technical service industry, specifically in engineering and technical research and development [1] - The registered address is located in the Tianjin Free Trade Zone, specifically at the intersection of Central Avenue and East Fifth Road [1] Shareholding Structure - Luoyang Huaron Biotechnology Co., Ltd. holds 100% of the shares in Huaron (Tianjin) Biotechnology Co., Ltd. [1] Business Scope - The business scope includes various technical services such as technology development, consulting, and transfer, as well as research and development in industrial enzyme preparations, fermentation process optimization, biochemistry products, biopesticides, and biological feed [1] - Additional areas of focus include cell technology research and application, medical research, information technology consulting, and the extraction, purification, and synthesis of marine biological active substances [1]

Core Viewpoint - Shanghai Baoji Pharmaceutical Co., Ltd. officially listed on the Hong Kong Stock Exchange on December 10, with an initial offering price of HKD 26.38 per share, opening at HKD 60.5, a surge of 129% [1][3] Group 1: Company Overview - Baoji Pharmaceutical is a biotechnology company established in 2019, focusing on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [5] - The company has a pipeline of 12 self-developed products, including three core products: KJ017, KJ103, and SJ02 (Sheng Nuwa®), along with four other clinical candidates and five preclinical assets [5] Group 2: Financial Performance - The company completed six rounds of financing from September 2020 to December 2024, raising a total of RMB 1.86645 billion, with the last round post-money valuation reaching RMB 4.87 billion [3][4] - For the fiscal years 2023, 2024, and the first half of 2025, the company's revenues were RMB 6.93 million, RMB 6.16 million, and RMB 4.199 million, respectively, with corresponding R&D expenditures of RMB 133 million, RMB 251 million, and RMB 111 million [6][7] Group 3: Market Potential - According to Frost & Sullivan, the clinical addressable market size for the four strategic therapeutic areas in China is expected to reach approximately RMB 50 billion by 2033 [6] - The market for large-volume subcutaneous delivery, particularly recombinant hyaluronidase, is projected to account for nearly RMB 7 billion, while the market for antibody-mediated autoimmune diseases is driven by IgG-related autoimmune diseases, estimated at RMB 26.7 billion [6] Group 4: Use of IPO Proceeds - The company plans to use the funds raised from the IPO for the R&D and commercialization of core products (including KJ017, KJ103, and SJ02), advancing existing pipeline products, optimizing proprietary synthetic biology technology, and enhancing production capacity [7]